Roopa Industries

Roopa Industries OCF/Debt

The Operating Cash Flow to Debt Ratio of Roopa Industries (530991.BO) as of Nov 3, 2026 is 223.18 %. In the previous year, Operating Cash Flow to Debt Ratio was -95.99 % — a change of -332.50% (higher).

OCF/Debt

223.18 %

YoY

-332.50%

Last updated:

Operating Cash Flow to Debt Ratio of Roopa Industries is 2026 223.18 % . Operating Cash Flow to Debt Ratio of Roopa Industries was 2025 -95.99 % . It decreases by -332.50% higher compared to the previous year.

The Roopa Industries OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2019
32.83 INR
Jan 1, 2020
19.96 INR
Jan 1, 2021
-4.13 INR
Jan 1, 2022
22.40 INR
Jan 1, 2023
49.45 INR
Jan 1, 2024
-13.09 INR
Jan 1, 2025
-95.99 INR
Jan 1, 2026
223.18 INR
The Roopa Industries OCF/Debt history
YEAROCF/DebtYoY
223.18 %-332.50%
-95.99 %+633.10%
-13.09 %-126.48%
49.45 %+120.76%
22.40 %-641.87%
-4.13 %-120.71%
19.96 %-39.21%
32.83 %-207.95%
-30.41 %+225.86%
-9.33 %-197.74%
9.55 %+87.07%
5.11 %-17.89%
6.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Roopa Industries Stock analysis

What does Roopa Industries do? Roopa Industries Ltd. manufactures pharmaceutical products, focusing on bulk drugs and drug intermediates. The company produces N,N-dicyclohexylcarbodiimide (DCC), Triphenyl Phosphine (TPP), 5-Cyano Phthalide, Glucosamine, and Bromine And Its Derivatives. Triphenyl Phosphine is used by manufacturers of Cephalosporin antibiotics and Statins, while Bromine And Its Derivatives serve agrochemicals, dyes, medical and veterinary products, water purification, and pesticides. Glucosamine is a key nutraceutical product. The primary buyers include pharmaceutical manufacturers, agrochemical companies, and producers of medical and veterinary compounds. The company's revenue streams come from the sale of these specialized chemical products to industries requiring bulk drugs and intermediates. Triphenyl Phosphine supports antibiotic and statin production, making it essential for pharmaceutical firms. Bromine And Its Derivatives cater to diverse sectors like agriculture, water treatment, and disinfection, with significant demand from agrochemical and medical product manufacturers. Glucosamine, as a sheet anchor product, drives sales in the nutraceutical market. Roopa Industries targets the pharmaceutical, agrochemical, and medical sectors with its product portfolio. The firm's focus on bulk drugs and intermediates positions it as a supplier to manufacturers of antibiotics, statins, and nutraceuticals. Its products are integral to the production of Cephalosporin group antibiotics, Statins, and various agrochemical applications, ensuring consistent demand from established industrial buyers. Roopa Industries is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Roopa Industries stock

Operating Cash Flow to Debt Ratio of Roopa Industries is 223.18 % in 2026.

Operating Cash Flow to Debt Ratio of Roopa Industries changed from -95.99 % to 223.18 %, representing a -332.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Roopa Industries since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Roopa Industries with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Roopa Industries

All Key Metrics — Roopa Industries